SAN DIEGO --(BUSINESS WIRE)--Sep. 8, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the
Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota SAN DIEGO (December 18, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic SAN DIEGO , April 9, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
Trial Data Expected to Provide Further Clinical Validation of Biocept's CTC and ctDNA Liquid Biopsy Testing and Platforms for Biomarker Detection in Patients Diagnosed with Non-Small Cell Lung Cancer
SAN DIEGO --(BUSINESS WIRE)--Jun. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing services to Quest patients for its Target Selector™
SAN DIEGO --(BUSINESS WIRE)--Jan. 6, 2023-- Biocept, Inc. (NasdaqCM: BIOC ) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc.
SAN DIEGO , Feb. 29, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the three months and 12 months
